Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

Yves Pommier; Mark J. O’Connor; Johann de Bono

doi:10.1126/scitranslmed.aaf9246

You are currently viewing the abstract.

Log in to view the full text

AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.

Log in through your institution

More options

Purchase digital access to this article

Download and print this article for your personal scholarly, research, and educational use.

Purchase this issue in print

Buy a single issue of Science for just $15 USD.

This article has a correction. Please see:

Erratum for the Perspective: “Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action” by Y. Pommier, M. J. O’Connor, J. de Bono - December 07, 2016

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP “trapping” and what this means for both clinical monotherapy and combination with chemotherapeutic agents.

View Full Text

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

This article has a correction. Please see:

Abstract

Science Translational Medicine

Article Tools